Literature DB >> 25305313

Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy.

Nataša Obermajer1, Felix C Popp2, Yorick Soeder2, Jan Haarer2, Edward K Geissler2, Hans J Schlitt2, Marc H Dahlke2.   

Abstract

The ultimate goal in transplantation medicine is the promotion of operational tolerance. Although Th cells of the Th17 type have been predominantly associated with rejection of allogeneic solid organ grafts, regulatory T (T(reg)) cells appear to foster operational tolerance. Induced T(reg) and Th17 cells have a higher lineage plasticity than has been recognized thus far. We found that when mesenchymal stem cells (MSCs) were used to induce long-term acceptance of allogeneic heart grafts in mice, the induction of T(reg) cells was preceded by development of a CD11b(hi)Gr1(int) myeloid-derived immunosuppressive cell-mediated Th17 response. Substantial suppression of Foxp3(+) T(reg) cell generation from retinoic acid receptor-related orphan receptor γ(-/-) T cells by MSCs revealed that retinoic acid receptor-related orphan receptor γ is a common factor in the differentiation of T(reg) and Th17 cells. Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-primed allograft mouse recipients resulted in a reduction of IL-17A production and an increase in the Foxp3(+) T(reg) cell fraction. Furthermore, identification of IL-17A(+) Foxp3(+) double-positive and ex-IL-17-producing IL-17A(neg)Foxp3(+) T cells strongly argues for direct conversion of Th17 cells into T(reg) cells as the underlying mechanism of immune regulation in MSC-mediated allograft survival. The Th17 into T(reg) conversion identified in this study constitutes an important immunological mechanism by which MSC-induced myeloid-derived immunosuppressive cells mediate operational transplant tolerance. The possibility to create T(reg) cell-regulated operational tolerance in the absence of complete immune suppression provides strong clinical implications for cell therapy-assisted minimization protocols.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25305313     DOI: 10.4049/jimmunol.1401776

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

Review 2.  The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Authors:  F Carty; B P Mahon; K English
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

Review 3.  Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer.

Authors:  Matteo Bellone; Arianna Brevi; Samuel Huber
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

Review 4.  Advances in islet encapsulation technologies.

Authors:  Tejal Desai; Lonnie D Shea
Journal:  Nat Rev Drug Discov       Date:  2016-12-23       Impact factor: 84.694

Review 5.  Tissue Engineering Approaches to Modulate the Inflammatory Milieu following Spinal Cord Injury.

Authors:  Courtney M Dumont; Daniel J Margul; Lonnie D Shea
Journal:  Cells Tissues Organs       Date:  2016-10-05       Impact factor: 2.481

Review 6.  Regulatory T Cells: Central Concepts from Ontogeny to Therapy.

Authors:  Bernard Khor
Journal:  Transfus Med Rev       Date:  2016-07-26

Review 7.  T-cell involvement in sex differences in blood pressure control.

Authors:  G Ryan Crislip; Jennifer C Sullivan
Journal:  Clin Sci (Lond)       Date:  2016-05-01       Impact factor: 6.124

Review 8.  Controlled release strategies for modulating immune responses to promote tissue regeneration.

Authors:  Courtney M Dumont; Jonghyuck Park; Lonnie D Shea
Journal:  J Control Release       Date:  2015-08-08       Impact factor: 9.776

9.  Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors.

Authors:  Yong Lu; Qiang Wang; Gang Xue; Enguang Bi; Xingzhe Ma; Aibo Wang; Jianfei Qian; Chen Dong; Qing Yi
Journal:  Cancer Cell       Date:  2018-06-11       Impact factor: 31.743

10.  Human umbilical cord derived mesenchymal stem cells promote interleukin-17 production from human peripheral blood mononuclear cells of healthy donors and systemic lupus erythematosus patients.

Authors:  S Ren; J Hu; Y Chen; T Yuan; H Hu; S Li
Journal:  Clin Exp Immunol       Date:  2015-12-16       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.